OOIR: Observatory of International Research

Papers

(The median citation count of Trends in Cancer is 5. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Revumenib: a new era in acute leukemia treatment	355
Subscription & copyright page	230
FBXW10: a male-biased E3 ligase in liver cancer	229
Spliced to kill: RNA mis-splicing derived cancer neoantigens	206
Platelets: tailoring metastasis treatment	189
Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology	181
Clinical perspective and treatment of immune-related colitis after cancer immunotherapy	179
Engineering growth factor ligands and receptors for therapeutic innovation	179
Tumor-resident microbes: the new kids on the microenvironment block	171
Cancer evolution: from Darwin to the Extended Evolutionary Synthesis	161
Navigating life as an early career researcher	159
Subscription and copyright page	157
Advisory Board and Contents	155
Subscription & copyright page	143
Onco-condensates: formation, multi-component organization, and biological functions	141
Accessing the vasculature in cancer: revising an old hallmark	140
Leveraging circulating microbial DNA for early cancer detection	132
Engine shutdown: migrastatic strategies and prevention of metastases	131
Emerging signaling mediators in the anorexia–cachexia syndrome of cancer	124
Radiotherapy and immunotherapy: open questions and future strategies	119
Molecular insights into SMARCA2 degradation in SMARCA4-mutant lung cancers	97
Subscription & copyright page	93
GOT2 consider the tumor microenvironment	92
Recent developments in myeloid immune modulation in cancer therapy	89
The evolving landscape of brain metastasis: volume II	87

Neural hijacking in cancer metabolism: from nutrients to organelles	87
Oncogenic competence: balancing mutations, cellular state, and microenvironment	83
cGAS–STING and the deadly CIN: how chronic inflammation represents a therapeutic vulnerability in chromosomally unstable cancers	83
Chromatin as an old and new anticancer target	82
Benefits and opportunities of the transgenic Oncopig cancer model	81
Cell death, therapeutics, and the immune response in cancer	79
Targeting the Hippo pathway in cancer: kidney toxicity as a class effect of TEAD inhibitors?	79
Diet, nutrient supply, and tumor immune responses	75
Crosstalk of T cells within the ovarian cancer microenvironment	71
Advancements in combining targeted therapy and immunotherapy for colorectal cancer	70
Tumor immunology CRISPR screening: present, past, and future	70
Chromosomal instability and aneuploidy as causes of cancer drug resistance	69
Regulation of metastatic organotropism	67
Gut microbiota – a double-edged sword in cancer immunotherapy	66
The gut–liver axis: host microbiota interactions shape hepatocarcinogenesis	63
Nonrepair functions of DNA mismatch repair proteins: new avenues for precision oncology	61
Advisory Board and Contents	60
Subscription & copyright page	59
Cancer immunotherapeutic challenges from autophagy-immune checkpoint reciprocal regulation	58
Cancer catecholamine conundrum	58
Advisory Board and Contents	57
Scaling data toward pan-cancer foundation models	57
Subscription & copyright page	55
Advisory Board and Contents	55
Palmitate paves the way to lung metastasis	54
Organellar pH as an emerging vulnerability to exploit in cancer	54
Inflammation: the incubator of the tumor microenvironment	53
Insights on ErbB glycosylation – contributions to precision oncology	53
Genetic immune escape in cancer: timing and implications for treatment	52
The emerging field of oncolytic virus-based cancer immunotherapy	51
Clinical and translational relevance of intratumor heterogeneity	49
Transcriptional regulation of hypoxic cancer cell metabolism and artificial intelligence	48
Emerging mechanisms of telomerase reactivation in cancer	47
Prospects for understanding and exploiting the consequences of hyperactivation lethality	47
Subscription & copyright page	47
Advancing cancer precision surgery with the tumor coagulome	46
Subscription and copyright page	46
B7-H3: a robust target for immunotherapy in prostate cancer	46
Updating cancer research with patient-focused networks	45
Advisory Board and Contents	45
Molecular and clinical insights into early-onset endometrial cancer	45
Advisory Board and Contents	45
Advisory Board and Contents	44
Endogenous and imposed determinants of apoptotic vulnerabilities in cancer	44
Advisory Board and Contents	44
Circulating cell-free DNA-based multi-cancer early detection	43
Cuproptosis in cancer: from molecular mechanisms to therapeutic intervention	43
RHOA takes the RHOad less traveled to cancer	42
Redefining precision cancer prevention to promote health equity	42
Stress granules and hormetic adaptation of cancer	42

Advisory Board and Contents	41
Gastric cancer immunosuppressive microenvironment heterogeneity: implications for therapy development	41
Advisory Board and Contents	41
CAR T cell persistence in cancer	40
The promise of TIL therapy for glioblastoma	40
Leveraging space innovations for cancer breakthroughs on Earth	40
Targeting TIM-3 to halt lung precancer progression	40
Advisory Board and Contents	40
Beyond safety: suicide systems in cell-based cancer therapies	40
A macrophage-neutrophil program drives mammary carcinogenesis	39
Subscription & copyright page	39
Time-of-day dependency of adoptive cell therapies	39
RNA vaccines for cancer: revolutionizing immunization strategies	39
Advisory Board and Contents	38
Dissecting liver tumor heterogeneity to improve health equity	37
Cross-dressing of dendritic cells strengthens antitumor immunity	37
The evolving posology and administration of immune checkpoint inhibitors: subcutaneous formulations	36
Orchestrating tumor-immune epigenetics via SERT–H3Q5ser axis	36
Metabolism and epigenetics: drivers of tumor cell plasticity and treatment outcomes	36
Branched chain amino acids and their aberrant metabolism in cancer	36
Neoantigen-directed therapeutics in the clinic: where are we?	35
A tipping point in cancer epidemiology: embracing a life course exposomic framework	35
Immune response and inflammation in cancer health disparities	34
Functional heterogeneity of fibroblasts in primary tumors and metastases	33
Advisory Board and Contents	32
Subscription & copyright page	32
Ferroptosis vulnerability in FLT3-mutant leukemia	32
Advisory Board and Contents	31
Epigenetic basis and targeting of cancer metastasis	30
Advisory Board and Contents	30
Tumor-draining lymph nodes – friend or foe during immune checkpoint therapy?	30
Targeting myeloid cells for cancer immunotherapy: Siglec-7/9/10/15 and their ligands	29
Engineered bacterial therapeutics for detecting and treating CRC	29
ApCAFs: spatial niches and therapeutic insights across cancers	29
In vivo macrophage engineering as novel therapeutic strategy against liver metastasis	28
Clonal evolution and hierarchy in myeloid malignancies	28
Dying to survive: harnessing inflammatory cell death for better immunotherapy	28
Subscription & copyright page	28
Space in cancer biology: its role and implications	28
Subscription & copyright page	27
Next-generation cancer vaccines and emerging immunotherapy combinations	27
Advisory Board and Contents	27
A new enhancer for anti-PD-1/PD-L1 immunotherapy: PCSK9 inhibition	27
The development of therapy related myeloid neoplasms in childhood cancer survivors	27
Addressing the genetic/nongenetic duality in cancer with systems biology	26
IL-33 and ILC2 in pancreatic cancer: good, bad or a bit of both?	26
Genitourinary cancer neoadjuvant therapies: current and future approaches	25
Using Drosophila to uncover the role of organismal physiology and the tumor microenvironment in cancer	25
Mapping heterogeneity in the tumor microenvironment of renal cell carcinoma through single-cell omics	25
Immunomodulation by endothelial cells: prospects for cancer therapy	25
NETscape or NEThance: tailoring anti-cancer therapy	25
Lifileucel: the first cellular therapy approved for solid tumours	25
Epigenetic reprogramming in pediatric gliomas: from molecular mechanisms to therapeutic implications	25
Subscription & copyright page	25
Successfully targeting the cancer system with metronomics for medulloblastoma	24
CRISPR tools for T cells: targeting the genome, epigenome, and transcriptome	24
Persisting cancer cells are different from bacterial persisters	24
IGSF3-mediated potassium dysregulation promotes neuronal hyperexcitability and glioma progression	23
The extracellular matrix in cancer: from understanding to targeting	23
Future perspectives on engineered T cells for cancer	23
Embracing diversity: macrophage complexity in cancer	23
Tissue architecture in tumor initiation and progression	23
Think zebras: challenges and opportunities for treating rare cancers	22
NRG1 and NRG2 fusion positive solid tumor malignancies: a paradigm of ligand-fusion oncogenesis	22
Emerging and extensive clonal evolution in the pancreas	22
Deciphering the roles of ABCB5 in normal and cancer cells	22
How cancer cells make and respond to interferon-I	22
Self-reactive, innate-like T cells enhance cytotoxicity and immunosurveillance	21
Advancing human leukocyte antigen-based cancer immunotherapy: from personalized to broad-spectrum strategies for genetically heterogeneous populations	21
Poised epigenetic states dictate metastatic fitness	21
New York’s Polyethnic-1000: a regional initiative to understand how diverse ancestries influence the risk, progression, and treatment of cancers	21
Subscription & copyright page	20
Enhancing dendritic cells by inhibiting BCL2	20
TET2, tumor control, and CAR T cell hyperproliferation	20
Fueling the revolution: RIBOTACs manipulating RNA decay	19
Acetylation: a new target for protein degradation in cancer	19
Bone marrow microenvironment: roles and therapeutic implications in obesity-associated cancer	19
Defining obesity in the context of cancer: thinking beyond body mass index	19
Hypoxia orchestrates the lymphovascular–immune ensemble in cancer	19
The clinical landscape of CAR-engineered unconventional T cells	19

Small cell lung cancer profiling: an updated synthesis of subtypes, vulnerabilities, and plasticity	18
Dynamic immune signatures as biomarkers for irAEs	18
Circulating extracellular vesicles and tumor cells: sticky partners in metastasis	18
Revisiting the HIF switch in the tumor and its immune microenvironment	18
Every patient	18
Extracellular vesicle lipids in cancer immunoevasion	18
Towards enhancing the predictive value of the microbiota for cancer immunotherapy	18
Time to heal: inhibiting fibrosis prevents glioblastoma recurrence	18
Interferon epsilon and ovarian cancer	17
Current landscape of CD3 bispecific antibodies in hematologic malignancies	17
Navigating the biophysical landscape: how physical cues steer the journey of bone metastatic tumor cells	17
Subscription & copyright page	17
Intracranial CAR-T cell delivery in glioblastoma patients	17
A growing entourage for heterotypic circulating tumor cell clusters	17
Advisory Board and Contents	17
Tackling the next decade of cancer research	17
Exploiting T cell signaling to optimize engineered T cell therapies	17
Regulated cell death modalities: breaking resistance of temozolomide glioblastoma therapy	16
Spatially resolving cancer: from cell states to therapy	16
The tumor-draining lymph node as a reservoir for systemic immune surveillance	16
Mechanisms of T cell exhaustion guiding next-generation immunotherapy	16
Limited dsRNA editing impedes leukemia stem cells	16
Tissue mechanics in tumor heterogeneity and aggression	16
Intratumoral immune cell manipulations as a strategy to enhance cancer vaccine efficiency	15
Subscription & copyright page	15
Advisory Board and Contents	15
A biopsychosocial model to understand racial disparities in the era of cancer immunotherapy	15
Harnessing FLASH irradiation to improve immunotherapy of medulloblastoma	15
Wargaming cancer: a strategy for future precision oncology?	15
mtDNA transfer from senescent cancer cells to MDSCs promotes immunosuppression	15
Into the era of mycobiome-driven cancer research	14
Modeling tumor plasticity in organoid models of human cancer	14
Spatial promoter–enhancer hubs in cancer: organization, regulation, and function	14
Targeting phagocytosis to enhance antitumor immunity	14
Adaptive inhibition of CGAS signaling by TREX1	14
Lifestyle and host determinants of antitumor immunity and cancer health disparities	14
KRAS inhibitors: resistance drivers and combinatorial strategies	14
Reductive stress in cancer: coming out of the shadows	14
Subscription & copyright page	13
Impact of tissue-agnostic approvals on management of primary brain tumors	13
On the path to equity in cancer research and care	13
Ancestry-defined molecular taxonomy of prostate cancer	13
Many faces, many places: delving deeper into CAF heterogeneity in NSCLC	13
State-matched organoid models to fight pancreatic cancer	13
Subscription & copyright page	13
Label-free optical imaging for brain cancer assessment	13
Lost but not least: Y chromosome loss as a driver of cancer	12
Necroptosis and tumor progression	12
Myeloid cell path to malignancy: insights into liver cancer	12
Polo-like kinases as immune modulators: a new frontier in cancer immunotherapy	12
Subscription & copyright page	12
The peritumor microenvironment: physics and immunity	12
Advances in targeting RNA modifications for anticancer therapy	12
Subscription & copyright page	12
Advisory Board and Contents	11
Immunometabolism of CD8+ T cell differentiation in cancer	11
Host and microbiome lipid metabolism in colorectal cancer development and therapy	11
Immune organoids: from tumor modeling to precision oncology	11
Leveraging immunologically based therapies to treat diffuse large B-cell lymphoma	11
When breaks get hot: inflammatory signaling in BRCA1/2-mutant cancers	11
Epigenetic control of immunoevasion in cancer stem cells	11
Drug independence and the curability of cancer by combination chemotherapy	11
Advisory Board and Contents	11
The emerging roles of the urea cycle in tumor microenvironment and therapies	11
Neuro-immune interactions and immuno-oncology	11
Emerging roles of nucleotide metabolism in cancer	11
The future of cancer research: invest now	10
Low tumor mutational burden and immunotherapy in gliomas	10
Subscription and copyright page	10
EZHIP’s role in diffuse midline glioma: echoes of oncohistones?	10
Metabolic landscape of disseminated cancer dormancy	10
An epigenetic signature in CD19-CAR T cells predicts clinical outcome	10
γδT cells and breast cancer: wicked allies	10
Advisory Board and Contents	10
Advisory Board and Contents	10
Treatment of patients with pMMR GI cancers with tumor-infiltrating lymphocytes (TIL): a reality?	10
Targeting vulnerabilities of aneuploid cells for cancer therapy	10
Diversity upon diversity: linking DNA double-strand break repair to blood cancer health disparities	10
CX3CL1: a key switch of cell death immunogenicity	10
Immune cells in residual disease and recurrence	9
Small molecules targeting microRNAs: new opportunities and challenges in precision cancer therapy	9
Optimizing the future: how mathematical models inform treatment schedules for cancer	9
Trends in cancer imaging	8
Targeting cancer stem cells in multiple myeloma	8
Neuronal and tumourigenic boundaries of glioblastoma plasticity	8
Advisory Board and Contents	8
Generation of tumor neoantigens by RNA splicing perturbation	8
Cancer fitness genes: emerging therapeutic targets for metastasis	8
CD4+ T cells in antitumor immunity	8
Subscription & copyright page	8
Immune mechanisms of toxicity from checkpoint inhibitors	8
Plastic persisters: revival stem cells in colorectal cancer	8
Therapeutic targeting of regulatory T cells in cancer	8
The urgent need to improve childhood cancer cachexia	8
Anxiolytics cause anxiety in pancreatic cancer	8